The Tissue and Blood Bank Core for the Lung Cancer SPORE will serve as a shared resource for all five main Research Projects and for the Career Developmental Research Programs. The Core will collect , process, distribute and store tissue and body fluid specimens as requested by the investigators. Triage and distribution of all specimens will be prioritized according to a plan established with all SPORE investigators, and approved by the Tissue and Blood Bank Core Pathologists. The Core will procure and triage fresh human lung tissue, including tumor, adjacent uninvolved, and normal tissues distal from the tumor and bronchial biopsies of the normal and abnormal airway, from lung cancer patients undergoing resections or bronchoscopies, as well as individuals undergoing these procedures for reasons other than lung cancer. After triage under sterile conditions, tissues designated by the Core Pathologist as normal or abnormal will be either immediately distributed to investigators for tissue culture, protein analysis, RNA analysis, or DNA analysis (Projects 1, 2, 3), or will be stored for future use (Project 5). Lymphocytes and plasma will be separated from other blood components and used immediately or stored for future analysis (Projects 1, 5). Fragments of tissue will also be formalin-fixed or paraffin embedding (Project 3). Some frozen or paraffin embedded specimens will be sectioned, examined by a Core Pathologist and normal and abnormal area separated by microdissection (Projects 1 and 2). Bronchoalveolar lavage fluid and areas of the esophagus and lung of patients microdissection (Projects 1 and 2). Bronchoalveolar lavage fluid and areas of the esophagus and lung of patients undergoing gene therapy clinical trial will also be collected by the Core (Project 4). For Project 3, monitoring of immune system reactivity to cycle B1 peptides will be carried out using peripheral blood lymphocytes isolated from lung cancer patients. Tissue/fluid procurement will be linked and complementary to activities already on-going by the UPCI Lung Cancer Program, which has been collecting tissues and blood for NIH-sponsored research projects and other research undertaken by the Program members. However, to meet the special requirements of the SPORE, the Core will require additional resources and personnel. The Core will maintain a database containing demographic and medical information collected from medical research and through a questionnaire to be distributed to subjects. All tissues will be information collected from medical research and through a questionnaire to be distributed to subjects. All tissues will be collected through IRB-approved protocols on which Tissue and Blood Bank Core pathologists will be co-investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-02
Application #
6643626
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-05-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Zhou, Jingjiao; Qu, Zhaoxia; Sun, Fan et al. (2017) Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation. Cancer Immunol Res 5:257-268
Leng, Shuguang; Wu, Guodong; Klinge, Donna M et al. (2017) Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget 8:63978-63985
Hopkins, Kathleen G; Ferson, Peter F; Shende, Manisha R et al. (2017) Prospective study of quality of life after lung cancer resection. Ann Transl Med 5:204
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944

Showing the most recent 10 out of 191 publications